EU/3/20/2288: Orphan designation for the treatment of myelodysplastic syndromes



On 26 June 2020, orphan designation EU/3/20/2288 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for magrolimab for the treatment of myelodysplastic syndromes.

The sponsorship was transferred to Gilead Sciences Ireland UC, Ireland, in September 2020.

Key facts

Active substance
Intended use
Treatment of myelodysplastic syndromes
Orphan designation status
EU designation number
Date of designation

Gilead Sciences Ireland UC
Ida Business & Technology Park
Carrigtohill T45 DP77

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating